Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.
Three chimpanzees immunized with recombinant gp120 from human immunodeficiency virus type 1 (HIV-1) strain MN and 1 control animal were challenged intravenously with a primary isolate of HIV-1SF2. Viral infection was detected in the control animal by viral culture, polymerase chain reaction, and multiple serologic assays beginning 2 weeks after infection. Markers of HIV-1 infection were not detected in any of the gp120-vaccinated animals during 12 months of follow-up. Antisera from the gp120-immunized chimpanzees were unable to neutralize the challenge virus cultured in peripheral blood mononuclear cells (PBMC). These studies demonstrate that immunization with recombinant gp120 derived from a T cell-adapted isolate prevented infection by a heterologous primary isolate of HIV-1. The results suggest that in vitro virus neutralization assays utilizing primary isolates cultured in PBMC may be imperfect indicators of protection in vivo.
Berman
P W
PW
Department of Immunology, Genentech, Inc., South San Francisco, California 94080, USA.
Murthy
K K
KK
Wrin
T
T
Vennari
J C
JC
Cobb
E K
EK
Eastman
D J
DJ
Champe
M
M
Nakamura
G R
GR
Davison
D
D
Powell
M F
MF
Bussiere
J
J
Francis
D P
DP
Matthews
T
T
Gregory
T J
TJ
Obijeski
J F
JF
D016915:AIDS Vaccines; D000818:Animals; D001483:Base Sequence; D017931:DNA Primers / Q000737:chemistry; D004279:DNA, Viral / Q000032:analysis; D015483:HIV Antibodies / Q000032:analysis; D015488:HIV Antigens / Q000276:immunology; D015699:HIV Envelope Protein gp120 / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000235:genetics / Q000276:immunology* / Q000302:isolation & purification; D007114:Immunization; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008969:Molecular Sequence Data; D009500:Neutralization Tests; D002679:Pan troglodytes; D013601:T-Lymphocytes / Q000821:virology; D014614:Vaccines, Synthetic; D014776:Virus Cultivation
D016915:AIDS Vaccines; D017931:DNA Primers; D004279:DNA, Viral; D015483:HIV Antibodies; D015488:HIV Antigens; D015699:HIV Envelope Protein gp120; D014614:Vaccines, Synthetic